Tech Company Financing Transactions
Atsena Therapeutics Funding Round
Atsena Therapeutics, based in Durham, secured $150 million in investment from Bain Capital Ventures, Abingworth and Foundation Fighting Blindness.
Transaction Overview
Company Name
Announced On
4/2/2025
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series C
Investors
Proceeds Purpose
The company plans to use the Series C funding to progress its main lead candidate ASTN-201 further. It already has Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, showing the potential importance of this treatment in a condition with no approved therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
280 S Mangum St. 350
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Website
Email Address
Overview
ATSENA THERAPEUTICS is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Ritschel
Chief Operating Officer
Nasser Hassan
Chief Scientific Officer
Shannon Boye
Chief Technical Officer
Sanford Boye
VP - Manufacturing
Michael Kelly
Browse more venture capital transactions:
Prev: 4/2/2025: Cambrian Network venture capital transaction
Next: 4/2/2025: Adaptive Security venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs